Evidence map›Paper›PMID 34981419›Full record

SynthesisEndocrine2022

Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis.

Ping Zhong, Hai Zeng, Miaochun Huang, Wenbin Fu, Zhixia Chen

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Endocrine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 8 pooled it
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 8 syntheses or guidelines pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Management of obesity in advanced chronic liver disease.JHEP reports : innovation in hepatology · 2026
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Ping ZhongDepartment of Acupuncture and Moxibustion, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Hai ZengCollege of Traditional Chinese Medicine, Jinan University, Guangzhou, China.
Miaochun HuangEmergency Department, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
Wenbin FuDepartment of Acupuncture and Moxibustion, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China. fuwenbin@gzucm.edu.cn.
Zhixia ChenGuangdong Provincial Hospital of Chinese Medicine, Guangzhou, China. chenzx116@163.com.
Guangdong Provincial Hospital of Traditional Chinese Medicine · CNGuangzhou University of Chinese Medicine · CNJinan University · CN

Funding

scientific research project of guangdong provincial administration of traditional chinese medicine No. 2020KT1112
6 · The paper itself

Abstract

purposeThis meta-analysis aimed to assess the efficacy and safety of once-weekly semaglutide among adults with overweight or obesity.

methodsWe searched multiple electronic databases for randomized controlled trials that compared once-weekly semaglutide versus placebo in adults with overweight or obesity. The primary outcomes were the percentage change and absolute change in body weight. Secondary outcomes included achievement of categorical weight loss targets (at least 5, 10, 15, or 20%), cardiometabolic risk profiles, and health-related quality of life.

resultsThis meta-analysis included a total of four trials with 3447 patients. Once-weekly semaglutide was superior to placebo in terms of the percentage change and absolute change in body weight. Compared with placebo, once-weekly semaglutide also led to significant increases in the proportions of achievement of categorical weight reduction targets. Moreover, once-weekly semaglutide induced superior reductions in waist circumference and body-mass index compared with placebo. Furthermore, the effect on improving other cardiometabolic risk factors and health-related quality of life was more pronounced for once-weekly semaglutide relative to placebo.

conclusionAmong adults with overweight or obesity, once-weekly semaglutide could result in clinically meaningful weight loss, which was a promising therapy for treating overweight or obesity.

Indexed as

Diabetes Mellitus, Type 2OverweightAdultGlucagon-Like PeptidesHumansHypoglycemic AgentsObesityQuality of LifeSemaglutideGlucagon-Like PeptidesHypoglycemic AgentsSemaglutideMeta-analysisObesityOnce-weekly semaglutideOverweightWeight management

Identifiers

PMID34981419
OpenAlexW4206202672

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.